Predictive Technology Group Announces Presentations of Clinical Research Relating to the Role of Genetics in Endometriosis at the Society for Reproductive Investigation Meeting
SALT LAKE CITY, UT –March 13, 2018 – Predictive Technology Group, Inc. (OTCPINK: PRED), a life-sciences technology company, announces new clinical data relating to the role of genetics in the development of endometriosis. These data were featured in three presentations by its development partner Juneau Biosciences, LLC at the Society for Reproductive Investigation’s (SRI) 65th Annual Scientific Meeting. The meeting was held March 5-10, 2018 in San Diego. Predictive Technology Group’s wholly owned subsidiary Predictive Therapeutics is developing novel therapeutics and proprietary gene-based non-invasive diagnostics for endometriosis.
Highlights of the presentations are as follows:
- “Rare Synonymous Mutations Show Strong Association with Endometriosis.” Juneau Biosciences’ Chief Science Officer Hans Albertsen, Ph.D., in an oral presentation, presented an analysis of 1,077 study participants with surgically diagnosed endometriosis, indicating that low-frequency DNA variants may play a role in the genetic predisposition of this disease even when they do not change the amnio acid building blocks for the encoded protein.
- “A Family with over 200 Women with Confirmed Endometriosis Suggesting Autosomal Dominant Influence.” Juneau Biosciences’ CEO Kenneth Ward, M.D. presented a poster highlighting the study of familial endometriosis using a unique genealogy database of 32 million ancestors of the present population of the western U.S. The study shows a high incidence of surgically proven endometriosis in the recent generations of a single family with endometriosis spanning 19 generations. Millions of women may carry the risk factor described in this study.
- “Large Effect Mutations Found in Endometriosis Genes Implicated by GWAS.” Ward also presented data providing the first comprehensive study of mutations in genes implicated by previous genome-wide associated studies (GWAS). The identified mutations are strong risk factors for developing endometriosis, distinct from the much weaker signals observed in GWAS. The discovery of mutations having large effects confirm a critical role for these genes in the pathogenesis of endometriosis.
“We understand that endometriosis runs in families, and the precise genetic mechanisms behind this disorder are now coming into focus,” said Dr. Ward. “Results from Juneau’s studies are being assembled into genetic tests to more accurately diagnosis women with endometriosis symptoms, as well as predicting disease in women at high risk for developing this disorder.”
“Each of these studies addresses the tremendous value of research in the role genetics play in endometriosis,” said Bradley Robinson, President and CEO of Predictive Technology Group. “We look forward to incorporating these valuable insights into the development of genetically based test and targeted therapies that can be employed at a much earlier stage to help mitigate the effects of this disorder.”
About the Society for Reproductive Investigation’s (SRI) Annual Meeting
The SRI annual scientific meeting gathers leading scientists and clinical investigators to share cutting-edge information in reproductive sciences and women’s health. The 65th Annual Meeting featured an exciting lineup of distinguished lecturers, 12 mini-symposia sessions, several new investigator events, career development sessions, and scientific oral and poster presentations. More information is available at http://www.sri-online.org/.
About Predictive Technology Group, Inc.
Predictive Technology Group , Inc. aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focuses on endometriosis, scoliosis, degenerative disc disease and regenerative tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is at www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
LHA Investor Relations
Jody Cain, 310-691-7100